Healthcare [ 5/13 ] | Drug Manufacturers - General [ 144/159 ]
NASDAQ | Common Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Feb 29, 24 | -0.01 Decreased by -150% | -0.03 Increased by +66.67% |
| Nov 1, 23 | -0.05 Decreased by -400% | -0.04 Decreased by -25% |
| Aug 2, 23 | -0.04 Increased by +63.64% | -0.04 |
| May 3, 23 | -0.04 Increased by +50% | -0.03 Decreased by -33.33% |
| Mar 1, 23 | 0.02 Decreased by -50% | -0.01 Increased by +300% |
| Oct 27, 22 | -0.01 Increased by +66.67% | -0.06 Increased by +83.33% |
| Aug 3, 22 | -0.11 Decreased by -650% | -0.06 Decreased by -83.33% |
| May 4, 22 | -0.08 Decreased by -1.85 K% | -0.02 Decreased by -300% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 66.06 M Decreased by -26.5% | -19.31 M Decreased by -275.7% | Decreased by -29.23% Decreased by -411.19% |
| Jun 30, 23 | 80.17 M Decreased by -15.11% | -17.56 M Increased by +74.9% | Decreased by -21.9% Increased by +70.43% |
| Mar 31, 23 | 85.97 M Decreased by -9.15% | -16.46 M Increased by +47.85% | Decreased by -19.15% Increased by +42.6% |
| Dec 31, 22 | 90.25 M Decreased by -37.54% | 856 K Decreased by -94.18% | Increased by +0.95% Decreased by -90.68% |
| Sep 30, 22 | 89.88 M Decreased by -36.72% | -5.14 M Increased by +60.92% | Decreased by -5.72% Increased by +38.23% |
| Jun 30, 22 | 94.44 M Decreased by -38.87% | -69.96 M Decreased by -995.95% | Decreased by -74.07% Decreased by -1.57 K% |
| Mar 31, 22 | 94.63 M Decreased by -33.44% | -31.56 M Decreased by -1.84 K% | Decreased by -33.35% Decreased by -2.82 K% |
| Dec 31, 21 | 144.49 M Decreased by -13.61% | 14.7 M Increased by +198.38% | Increased by +10.17% Increased by +245.38% |
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally to wholesalers and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.